Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, reinforcing investor hopes that the data would boost chances of a buyout. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) shares after opening at $5.00 moved to $5.09 on last trade day and at the end of the day closed at $4.49. Company price to cash ratio as 6.17. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) showed a positive weekly performance of 1.81%.
Pomerantz LLP announces the filing of a class action lawsuit against Allied Nevada Gold Corp. (NYSEMKT:ANV) and certain of its officers. The class action, filed in United States District Court, District of Nevada, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Allied Nevada between January 18, 2013 and August 5, 2013, both dates inclusive (the “Class Period”). Allied Nevada Gold Corp. (NYSEMKT:ANV) shares fell -6.35% in last trading session and ended the day on $3.39. ANV return on equity ratio is recorded as 1.40% and its return on assets is 0.70%. Allied Nevada Gold Corp. (NYSEMKT:ANV) yearly performance is -68.32%.
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, yesterday announced it will has entered a definitive agreement to sell its SUMAVEL® DosePro® Needle-free Delivery System (sumatriptan injection) migraine therapy business to Endo International plc (Nasdaq:ENDP) for $85 million in cash and milestone payments of up to $20 million. Zogenix, Inc. (NASDAQ:ZGNX) shares moved down -5.43% in last trading session and was closed at $2.44, while trading in range of $2.36 – $2.54. Zogenix, Inc. (NASDAQ:ZGNX) year to date (YTD) performance is -29.07%.
Net operating cash flow has significantly increased by 86.13% to -$1.12 million when compared to the same quarter last year. In addition, Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) has also vastly surpassed the industry average cash flow growth rate of -15.11%. Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) weekly performance is -5.04%. On last trading day company shares ended up $18.29. Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) distance from 50-day simple moving average (SMA50) is -2.07%. Analysts mean target price for the company is $24.71.